HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire

Human Immunology

Volumn 76, Issue 8, 2015, Pages 578-586

  Lauterbach, Nina ^a   Wieten, Lotte ^a   Popeijus, Herman E ^b   Voorter, Christina E M ^a   Tilanus, Marcel G J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

HLA E; NKG2A; NKG2C

Indexed keywords

HLA ANTIGEN CLASS 1; HLA G ANTIGEN; HLA-E ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; PEPTIDE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CHEMISTRY; DEGRANULATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; NATURAL KILLER CELL;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CELL DEGRANULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; PEPTIDES;

EID: 84953348755     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2015.09.003     Document Type: Article

References (52)

1. Moretta L., Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004, 23:255-259.
2. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 2004, 5:1260-1265.
3. Kaiser B.K., Barahmand-Pour F., Paulsene W., Medley S., Geraghty D.E., Strong R.K. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J. Immunol. 2005, 174:2878-2884.
4. Kaiser B.K., Pizarro J.C., Kerns J., Strong R.K. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6696-6701.
5. Lee N., Llano M., Carretero M., Ishitani A., Navarro F., Lopez-Botet M., et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:5199-5204.
6. Braud V.M., Allan D.S., O'Callaghan C.A., Soderstrom K., D'Andrea A., Ogg G.S., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
7. Iwaszko M., Bogunia-Kubik K. Clinical significance of the HLA-E and CD94/NKG2 interaction. Arch. Immunol. Ther. Exp. (Warsz) 2011, 59:353-367.
8. Lodoen M.B., Lanier L.L. Viral modulation of NK cell immunity. Nat. Rev. Microbiol. 2005, 3:59-69.
9. Wieten L., Mahaweni N.M., Voorter C.E., Bos G.M., Tilanus M.G. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens 2014, 84:523-535.
10. Guma M., Angulo A., Vilches C., Gomez-Lozano N., Malats N., Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004, 104:3664-3671.
11. Guma M., Budt M., Saez A., Brckalo T., Hengel H., Angulo A., et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 2006, 107:3624-3631.
12. Lopez-Verges S., Milush J.M., Schwartz B.S., Pando M.J., Jarjoura J., York V.A., et al. Expansion of a unique CD57NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14725-14732.
13. Munoz-Cobo B., Solano C., Benet I., Costa E., Remigia M.J., de la Camara R., et al. Functional profile of cytomegalovirus (CMV)-specific CD8(+) T cells and kinetics of NKG2C(+) NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. J. Med. Virol. 2012, 84:259-267.
14. Beziat V., Dalgard O., Asselah T., Halfon P., Bedossa P., Boudifa A., et al. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur. J. Immunol. 2012, 42:447-457.
15. Foley B., Cooley S., Verneris M.R., Curtsinger J., Luo X., Waller E.K., et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J. Immunol. 2012, 189:5082-5088.
16. Della Chiesa M., Muccio L., Moretta A. CMV induces rapid NK cell maturation in HSCT recipients. Immunol. Lett. 2013, (155):11-13.
17. Kren L., Slaby O., Muckova K., Lzicarova E., Sova M., Vybihal V., et al. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance?. Neuropathology 2010, 31:129-134.
18. Benevolo M., Mottolese M., Tremante E., Rollo F., Diodoro M.G., Ercolani C., et al. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J. Transl. Med. 2011, 9:184.
19. Spaans V.M., Peters A.A., Fleuren G.J., Jordanova E.S. HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J. Transl. Med. 2012, 10:184.
20. Kren L., Valkovsky I., Dolezel J., Capak I., Pacik D., Poprach A., et al. HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma. Diagn. Pathol. 2012, 7:58.
21. de Kruijf E.M., Sajet A., van Nes J.G., Natanov R., Putter H., Smit V.T., et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J. Immunol. 2010, 185:7452-7459.
22. Gooden M., Lampen M., Jordanova E.S., Leffers N., Trimbos J.B., van der Burg S.H., et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8 T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10656-10661.
23. Kren L., Fabian P., Slaby O., Janikova A., Soucek O., Sterba J., et al. Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. Pathol. Res. Pract. 2011, 208:45-49.
24. Tripathi P., Naik S., Agrawal S. HLA-E and immunobiology of pregnancy. Tissue Antigens 2006, 67:207-213.
25. Prigione I., Penco F., Martini A., Gattorno M., Pistoia V., Morandi F. HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 50:966-972.
26. Lee N., Goodlett D.R., Ishitani A., Marquardt H., Geraghty D.E. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J. Immunol. 1998, 160:4951-4960.
27. Maier S., Grzeschik M., Weiss E.H., Ulbrecht M. Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. Hum. Immunol. 2000, 61:1059-1065.
28. Ulbrecht M., Martinozzi S., Grzeschik M., Hengel H., Ellwart J.W., Pla M., et al. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J. Immunol. 2000, 164:5019-5022.
29. Heinzel A.S., Grotzke J.E., Lines R.A., Lewinsohn D.A., McNabb A.L., Streblow D.N., et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J. Exp. Med. 2002, 196:1473-1481.
30. Michaëlsson J., Teixeira de Matos C., Achour A., Lanier L.L., Karre K., Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J. Exp. Med. 2002, 196:1403-1414.
31. van Hall T., Oliveira C.C., Joosten S.A., OttenhoffT.H. The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect. 2010, 12:910-918.
32. Marin R., Ruiz-Cabello F., Pedrinaci S., Mendez R., Jimenez P., Geraghty D.E., et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003, 54:767-775.
33. Llano M., Lee N., Navarro F., Garcia P., Albar J.P., Geraghty D.E., et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur. J. Immunol. 1998, 28:2854-2863.
34. Miller J.D., Weber D.A., Ibegbu C., Pohl J., Altman J.D., Jensen P.E. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J. Immunol. 2003, 171:1369-1375.
35. Brooks A.G., Borrego F., Posch P.E., Patamawenu A., Scorzelli C.J., Ulbrecht M., et al. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. J. Immunol. 1999, 162:305-313.
36. Lauterbach N., Voorter C.E., Tilanus M.G. Molecular typing of HLA-E. Methods Mol. Biol. 2012, 882:143-158.
37. Sarkar S., van Gelder M., Noort W., Xu Y., Rouschop K.M., Groen R., et al. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol. Immunother. 2015, (64):951-963.
38. Lauterbach N., Wieten L., Popeijus H.E., Vanderlocht J., van Zon P.M., Voorter C.E., et al. Peptide-induced HLA-E expression in human PBMCs is dependent on peptide sequence and the HLA-E genotype. Tissue Antigens 2015, 85:242-251.
39. Cheent K.S., Jamil K.M., Cassidy S., Liu M., Mbiribindi B., Mulder A., et al. Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:16981-16986.
40. Vales-Gomez M., Reyburn H.T., Erskine R.A., Lopez-Botet M., Strominger J.L. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999, 18:4250-4260.
41. Cassidy S.A., Cheent K.S., Khakoo S.I. Effects of Peptide on NK cell-mediated MHC I recognition. Front. Immunol. 2014, 5:133.
42. Borrego F., Kabat J., Sanni T.B., Coligan J.E. NK cell CD94/NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes. J. Immunol. 2002, 169:6102-6111.
43. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
44. Dietrich J., Hou X., Wegener A.M., Pedersen L.O., Odum N., Geisler C. Molecular characterization of the di-leucine-based internalization motif of the T cell receptor. J. Biol. Chem. 1996, 271:11441-11448.
45. von Essen M., Menne C., Nielsen B.L., Lauritsen J.P., Dietrich J., Andersen P.S., et al. The CD3 gamma leucine-based receptor-sorting motif is required for efficient ligand-mediated TCR down-regulation. J. Immunol. 2002, 168:4519-4523.
46. Tripathi P., Agrawal S. The role of human leukocyte antigen E and G in HIV infection. AIDS 2007, 21:1395-1404.
47. Lozano J.M., Gonzalez R., Kindelan J.M., Rouas-Freiss N., Caballos R., Dausset J., et al. Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS 2002, 16:347-351.
48. Onno M., Pangault C., Le Friec G., Guilloux V., Andre P., Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J. Immunol. 2000, 164:6426-6434.
49. Yan W.H., Lin A., Chen B.G., Chen S.Y. Induction of both membrane-bound and soluble HLA-G expression in active human cytomegalovirus infection. J. Infect. Dis. 2009, 200:820-826.
50. Foley B., Cooley S., Verneris M.R., Pitt M., Curtsinger J., Luo X., et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012, 119:2665-2674.
51. Siewiera J., El Costa H., Tabiasco J., Berrebi A., Cartron G., Le Bouteiller P., et al. Human cytomegalovirus infection elicits new decidual natural killer cell effector functions. PLoS Pathog. 2013, 9:e1003257.
52. Lampen M.H., Hassan C., Sluijter M., Geluk A., Dijkman K., Tjon J.M., et al. Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol. Immunol. 2013, 53:126-131.